Skip to main content
European Radiology Experimental
Fig. 4 | European Radiology Experimental

Fig. 4

From: A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis

Fig. 4

A false-negative case for no-residual enhancement on CTHA-EM analysis showing residual tumor on first follow-up imaging 13.3 weeks later. a Pretreatment CTHA arterial phase showed hypervascular HCC (white arrow). b Posttreatment CTHA showed retention of contrast media in the tumor (white arrow). c Pre-treatment CTHA-EM image shown in inverted gray scale with HCC (white arrow). d Posttreatment CTHA-EM demonstrated lack of residual tumor enhancement at the target HCC or its feeding artery, therefore identified as “no-residual.” e First follow-up CT imaging (arterial phase) showed residual tumor (white arrow). f Second session of pretreatment CTHA confirmed residual tumor along the border of treated tumor (white arrow). Tumor progression instead of residual untreated tumor cannot be excluded due to long follow-up period from DEB-TACE procedure to first follow-up imaging. CTHA, Computed tomography hepatic arteriography; CTHA-EM, CTHA enhancement mapping; DEB-TACE, Drug-eluting beads transarterial chemoembolization; HCC, Hepatocellular carcinoma

Back to article page